PROF Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.84M

+88.47%

-0.278

+38.75%

7.08M

+170.4%

-0.273

-24.07%

7.78M

+252%

-0.257

-50.64%

Estimates Revision

The market is revising Upward the revenue expectations for Profound Medical Corp. (PROF) for FY2025, with the revenue forecasts being adjusted by 4.41% over the past three months. During the same period, the stock price has changed by 27.30%.

Revenue Estimates for FY2025

Revise Upward

+4.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.52%

In Past 3 Month

Stock Price

Go Up

+27.30%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.33 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

11.00

Averages

11.33

High

12.00

Current: 0.000

Low

11.00

Averages

11.33

High

12.00

Lake Street

Buy

maintain

$11 -> $12

2026-01-07

New

Reason

Lake Street

Price Target

$11 -> $12

2026-01-07

New

maintain

Buy

Reason

Lake Street raised the firm's price target on Profound Medical to $12 from $11 and keeps a Buy rating on the shares. Profound raised gross proceeds of $36M via a registered direct offering and $6.45M in a private placement late last year and with "any capital concerns now behind the company," investors can focus on Profound's fundamental performance, the analyst argues.

Raymond James

Michael Freeman

Strong Buy

Outperform

downgrade

$17 -> $11

2025-05-09

Reason

Raymond James

Michael Freeman

Price Target

$17 -> $11

2025-05-09

downgrade

Strong Buy

Outperform

Reason

Raymond James analyst Michael Freeman downgraded Profound Medical to Outperform from Strong Buy with a price target of $11, down from $17, after a top-line miss in Q1. With increasing evidence of TULSA's safety, efficacy, and breadth of application across prostate disease, the firm remains confident in TULSA's "candidacy as a standard-of-care procedure" should the Level 1 safety and efficacy data from the CAPTAIN trial continue to read out positively during the next few years, but the firm reset its price target and rating on peer multiple compression and on economic uncertainty potentially impacting TULSA's rate of adoption by private practices and institutions.

Lake Street

Benjamin Haynor

Strong Buy

Maintains

$17 → $11

2025-04-23

Reason

Lake Street

Benjamin Haynor

Price Target

$17 → $11

2025-04-23

Maintains

Strong Buy

Reason

Lake Street lowered the firm's price target on Profound Medical to $11 from $17 and keeps a Buy rating on the shares. Initial data from the CAPTAIN study, which the firm calls out as "the first-ever Level 1 study comparing two treatment modalities in prostate cancer," is set to be released at the American Urological Association later this week and Profound will also host an investor event next Monday during the conference, the analyst tells investors. While the firm says it anticipates "both will be well-received by investors and commercial payors," it is reducing its revenue multiple for Profound and its price target due to the recent market volatility and decline in comp group multiples.

Valuation Metrics

The current forward P/E ratio for Profound Medical Corp (PROF.O) is -7.41, compared to its 5-year average forward P/E of -8.12. For a more detailed relative valuation and DCF analysis to assess Profound Medical Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.12

Current PE

-7.41

Overvalued PE

-3.99

Undervalued PE

-12.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.46

Current EV/EBITDA

-6.23

Overvalued EV/EBITDA

-2.86

Undervalued EV/EBITDA

-12.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

17.16

Current PS

7.08

Overvalued PS

27.40

Undervalued PS

6.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PROF News & Events

Events Timeline

No data

News

8.5

2025-12-30Globenewswire

Profound Medical Completes $6.45 Million Private Placement to Expand Operations

8.5

2025-12-26Newsfilter

Profound Medical Corp. Raises $6.45 Million in Expanded Private Placement

8.5

2025-12-24Globenewswire

Profound Medical Raises $6.45 Million in Expanded Private Placement for Business Growth

People Also Watch

Frequently Asked Questions

What is Profound Medical Corp (PROF) stock price today?

The current price of PROF is 8.44 USD — it has decreased -0.47 % in the last trading day.

What is Profound Medical Corp (PROF)'s business?

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

What is the price predicton of PROF Stock?

What is Profound Medical Corp (PROF)'s revenue for the last quarter?

Profound Medical Corp revenue for the last quarter amounts to 5.29M USD, increased 86.76 % YoY.

What is Profound Medical Corp (PROF)'s earnings per share (EPS) for the last quarter?

Profound Medical Corp. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Profound Medical Corp (PROF)'s fundamentals?

How many employees does Profound Medical Corp (PROF). have?

Profound Medical Corp (PROF) has 131 emplpoyees as of January 10 2026.

What is Profound Medical Corp (PROF) market cap?

Today PROF has the market capitalization of 306.31M USD.